; PAK1. 8 These ArgBP2 binding proteins are involved in the regulation of the actin cytoskeleton, cell motility and shape, cell proliferation and survival.
In ArgBP2, the SH3-A, -B and -C domains ( Figure 2c ) interact with the proline-rich motifs of the nonreceptor tyrosine kinase ABL and Arg (SH3-A and -C) and/or of the proto-oncogene ubiquitin ligase CBL (SH3-B and -C). 7 CBL, which specifically targets activated protein tyrosine kinases and regulates their signaling, is a negative regulator of the activated ABL by mediating its ubiquitin-dependent degradation in the proteasome. 7 Binding of CBL to ABL depends on the presence of the adaptor protein, ArgBP2: phosphorylation of CBL and ArgBP2 by activated ABL kinases stabilizes the complex, thereby facilitating CBL-induced ubiquitination and the subsequent degradation of ABL and ArgBP2. 7 Interestingly, also CBL has been found to be a MLL fusion partner in a patient with de novo AML. The fact that multiple myeloma (MM) almost exclusively grows and expands in the bone marrow and develops devastating bone destruction suggests the importance of the bone marrow microenvironment in growth and survival of MM cells. We and others have previously demonstrated that the growth and survival of MM cells are potently enhanced by a cell-to-cell interaction between MM cells and osteoclasts, and that a vicious Letters to the Editor cycle is formed between MM cells and osteoclasts for their growth and bone destruction.
1,2 Importantly, osteoclasts also protect MM cells from apoptosis induced by doxorubicin, suggesting that increased osteoclast number and/or activity contribute to aggressiveness or drug resistance of MM cells. Interleukin (IL)-6 is regarded as a major growth-promoting and antiapoptotic factor for MM cells, and is mainly produced by bone marrow microenvironment in MM. The effects of osteoclasts in enhancing MM cell growth and survival are, however, only partially inhibited by abrogating IL-6 actions, despite an increased production of IL-6 by osteoclasts via the interaction with MM cells. 1 These results suggest that osteoclastderived factor(s) other than IL-6 is involved in osteoclastmediated enhancement of growth and survival of MM cells.
B-cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL), members of tumor necrosis factor (TNF) family, have been implicated as growth and survival factors for cytokine-stimulated MM cells.
3,4 B-cell-activating factor binds to three TNF receptor family members, B-cell maturation antigen (BCMA), transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), and BAFF receptor (BAFF-R), whereas APRIL binds to BCMA, TACI and heparan sulfate proteoglycans such as syndecan-1. 5 Multiple myeloma cells in primary culture constitutively express BCMA as well as syndecan-1, 3,4 whereas TACI is preferentially expressed by MM cells dependent on bone marrow microenvironment. 6 B-cell-activating factor receptor is expressed only occasionally.
3,4 Addition of BAFF and APRIL activates nuclear factor-kappaB (NF-kB), phosphatidylinositol-3 kinase (PI3K) to Akt and mitogen-activated protein kinase (MAPK) pathways and induces a strong upregulation of Mcl-1 and Bcl-2 antiapoptotic proteins in MM cells. 4 The serum levels of BAFF and APRIL are increased about fivefold in patients with MM as compared with healthy donors. 4 Analyses of BAFF and APRIL expression in cells from bone marrow microenvironment of MM patients by quantitative PCR or enzyme-linked immunosorbent assay revealed that CD14 þ cells and osteoclasts abundantly express both factors, whereas normal B cells, primary MM cells and bone marrow stromal cells produce much lower levels. 6 These results suggest that osteoclasts are among the predominant cell sources of BAFF and APRIL in the MM bone marrow microenvironment. Based upon these observations, a phase I/II clinical study of TACI-Fc fusion protein, a potent inhibitor for both BAFF and APRIL to abrogate BAFF and APRIL actions, in patients with refractory or relapsed MM, is ongoing. 7 However, the role of these osteoclast-derived factors in osteoclastmediated MM cell growth and survival is still unclear.
In order to clarify the importance of osteoclast-derived BAFF and APRIL in osteoclast-mediated MM cell growth and survival, we explored the effect of TACI-Fc as a decoy receptor for BAFF and APRIL on MM cell growth and survival in co-cultures of MM cells and osteoclasts. As we previously reported, 1 a large number of RPMI8226 cells as well as primary CD138
þ MM cells underwent apoptosis in serum-depleted conditions, whereas those co-cultured with osteoclasts remained alive. When TACIFc was added in co-cultures with osteoclasts, apoptosis of MM cells was substantially enhanced, indicating a supporting role for BAFF and APRIL in osteoclast-mediated MM cell growth and survival ( Figure 1) . Although an autocrine survival loop by BAFF and APRIL has been reported in RPMI8226 cell line, 4 TACI-Fc showed only minor inhibitory activity in these cells survival in the absence of osteoclasts ( Figure 1 ). As we and others reported, Figure 1 The effects of TACI-Fc on multiple myeloma (MM) cell survival. Osteoclasts (OCs) were generated from peripheral blood monocytes in the presence of 50 ng/ml soluble receptor activator of nuclear factor-kappaB (RANK) ligand (Pepro Tech, London, England) and 500 U/ml M-CSF (R&D Systems, Minneapolis, MN, USA), and isolated as previously described. 1 Multiple myeloma (MM) cells were isolated from bone marrow mononuclear cells from patients with MM by positive selection using anti-CD138-conjugated magnetic beads (Miltenyi Biotec, Auburn, CA, USA). Multiple myeloma cells were cultured in 24-well culture plates in the presence or absence of OCs in fresh alpha-MEM with 1% fetal bovine serum. The TACI-Fc (Alexis Biochemicals, Carlsbad, CA, USA) or control Fc (R&D System) was added at 10 mg/ml to the indicated wells. At day 3 of culture, cellular viability and apoptosis were determined by flow cytometric analysis of annexin V binding and propidium iodide (PI) uptake (MEBCYTO Apoptosis Kit; Medical and Biological Laboratories, Nagoya, Japan) according to the manufacturer's instructions. Samples were analyzed by EPICS-Profile (Coulter Electronics, Hialeah, FL, USA). Intact cells are located in the lower left quadrant of dot plots, whereas dead cells in the upper right quadrant. All procedures involving human specimens were performed according to the protocol approved by the institutional review board for human protection.
Letters to the Editor osteoclasts are able to enhance growth and survival of MM cells under cell-to-cell interactions with MM cells. 1, 2 Taken together, these results are consistent with the hypothesis that BAFF and APRIL play an important role in the formation of a vicious cycle between MM cells and osteoclasts under close cell-to-cell interactions in the MM bone marrow microenvironment. Such a hypothesis provides a rationale for the interference of the interactions between these factors and their cognate receptors by TACI-Fc as a novel therapeutic approach against MM.
The JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis Recently, several groups have reported independently, an acquired somatic point mutation in the JAK2 gene (V617F) in approximately 90% of patients with polycythaemia vera, as well as nearly half of patients with idiopathic myelofibrosis and essential thrombocytosis. [1] [2] [3] [4] In addition, some reports suggested that the V617F mutation is infrequent in myelodysplastic syndromes (MDS) (1-5%) and in acute myeloid leukemias (AML) (0% in AML without a history of chronic myeloproliferative disorder (CMPD), and 18% in AML M7). 2, 5, 6 However, CMPD and MDS can be difficult to classify, and cases with overlapping features between CMPD and MDS do exist, and should be included in the category of MDS/MPD recently defined in the new WHO classification. One of these borderline categories, in which the search for JAK2 mutations is of interest, is MDS/AML with fibrosis. In a recent issue of Leukemia, Ohyashiki et al., described the presence of JAK2 mutation in two of six MDS with fibrosis, but in none of the three cases each of AML, lymphoma, or chronic myeloid leukemia with fibrosis, nor in 38 cases of MDS without fibrosis. 7 The authors speculated, that either the JAK2 mutation is responsible for the development of secondary fibrosis in patients with MDS, or that cases exhibiting the JAK2 mutation rather represent CMPD with features of MDS, which should be categorized as MDS/MPD unclassifiable according to the WHO classification.
In order to answer this question, we analyzed 25 cases of MDS (n ¼ 17) and de novo AML (n ¼ 8) with fibrosis, 19 MDS (n ¼ 12) and de novo AML (n ¼ 7) without fibrosis, four cases of MDS/MPD unclassifiable, and 14 cases with reactive changes, for the presence of the JAK2 mutation. The group with fibrosis consisted of refractory cytopenia with multilineage dysplasia, (n ¼ 5); refractory anemia with excess of blasts (RAEB)-1, (n ¼ 2); RAEB-2, (n ¼ 10) and AML, (n ¼ 8), (M0, M5 (FAB), acute panmyelosis with myelofibrosis). Myelodysplastic syndromes with fibrosis was defined by peripheral blood, and bone marrow findings typical for MDS, including pancytopenia and dysplastic features in one ore more hematopoietic lineages and bone marrow fibrosis (Xgrade 2) in the absence of any signs of CMPD. Cytogenetic data were available in all but four cases, including þ 14, À7, del 13q, del 12p, del 5q, þ 8, t(2;10), del 20q and t(11;21) abnormalities. The presence of the V617F mutation was assessed on paraffin-embedded bone marrow trephine biopsies with two previously published strategies. 1, 4 The first approach represents an allele-specific multiplex PCR with one common reverse and two separate forward primers, one of them with a mismatch at the 3 0 -end specific for the
